EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, today announced the launch of BioFX® Liquid Nova-Stop Solution, a non-corrosive, non-hazardous stop solution for TMB microwell substrates.
“We know assay developers are always seeking the safest possible products that still deliver top performance,” says Joe Stich, vice president and general manager of SurModics’ IVD business. “BioFX Liquid Nova-Stop Solution represents a major improvement over traditional stop solutions that contain sulfuric acid or hydrochloric acid. It also delivers key performance in terms of minimal signal drift.”
ELISA assay kit manufacturers can include BioFX Liquid Nova-Stop Solution in their products without needing to label and ship the products as “corrosive.” This means added convenience for kit manufacturers and their customers, as well as reduced transportation costs by avoiding surcharges related to shipping corrosive or hazardous materials. This is particularly relevant as companies seek to comply with requirements of the United Nation’s Globally Harmonized System of Classification and Labeling of Chemicals (GHS).
In the U.S., GHS implementation occurs through the Occupational Health and Safety Administration’s revised Hazard Communication Standard (HCS). As of June 1, 2015, OSHA will require hazardous chemical labels to include pictograms and hazard and precautionary statements, among other items. Many standard TMB stop solutions containing hydrochloric or sulfuric acids will need to comply with GHS/OSHA labeling requirements. Because the new BioFX Liquid Nova-Stop Solution is non-corrosive and non-hazardous, no GHS labeling is required.
SurModics IVD offers a full range of innovative solutions, including custom formulations, for the in vitro diagnostics industry. To learn more, visit our website (www.surmodics.com/ivd), or contact customer service (952-500-7200 or email@example.com). More than 900 IVD products are available for online ordering at shop.surmodics.com.
About SurModics, Inc.
SurModics' mission is to exceed our customers' expectations and enhance the wellbeing of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include (i) surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities, and (ii) components for in vitro diagnostic tests and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.
SurModics and BioFX are registered trademarks of SurModics, Inc. and/or its affiliates.